solver.press

Pharmacological activation of c-di-GMP phosphodiesterases to disperse biofilm converts sessile biofilm-mode bacteria to planktonic mode, reducing effective MIC by ≥8-fold and eliminating the biofilm-specific antibiotic tolerance phenotype in ESKAPE pathogens

MedicineJul 27, 2026Evaluation Score: 71%

Adversarial Debate Score

50% survival rate under critique

Expert panel critique

Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.

Grok: {"code":"permission-denied","error":"Your team 66dc1710-5e0c-42e8-bdea-258e945fcd69 has either used all available credits or reached its monthly spending limit. To co...
Gemini: ** **Strengths:** The hypothesis is highly falsifiable, as the proposed \ge8-fold reduction in MIC and elimination of biofilm-specific tolerance can be directly measured using standard antimicrobial susceptibility testing on dispersed planktonic cells. **Weaknesses:** The hypothesis is comple...
Mistral: The hypothesis is falsifiable, mechanistically plausible, and supported by multiple lines of evidence from the literature (e.g., biofilm dispersal via c-di-GMP modulation, MIC reduction in planktonic cells). However, the owner’s validated experiments do not directly test this hypothesis, and the ...
ChatGPT: The hypothesis is falsifiable, but the cited excerpts do not directly demonstrate pharmacological c-di-GMP phosphodiesterase activation, a reproducible ≥8-fold MIC reduction, or complete elimination of biofilm-specific tolerance across ESKAPE pathogens. The owner’s validated experiments are unrel...
Claude: ** The hypothesis is scientifically coherent and falsifiable in principle, but none of the owner's validated experiments are relevant to c-di-GMP signalling, biofilm dispersal, or ESKAPE pathogen pharmacology — the ground-truth findings are entirely about ML precision arithmetic and drug-docking...

Supporting Research Papers

Computational Result

📖 Literature-assessed (LLM)· literature_meta

An LLM's reading of the literature — not computational verification.

C-di-GMP modulation shows promise but may not universally reduce antibiotic tolerance.

Method: literature_meta · Result: inconclusive · Confidence: 60%

Formal Verification

Z3 logical consistency:✅ Consistent

Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.

Experimental Validation Package

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

Pharmacological activation of c-di-GMP phosphodiesterases (PDEs) in established biofilms of ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.) will (a) reduce intracellular c-di-GMP by ≥70% within 2h of treatment, (b) trigger measurable biofilm dispersal (≥50% biomass loss by crystal violet/CV or confocal biovolume), and (c) reduce the antibiotic concentration required to achieve 3-log10 CFU reduction (effective MIC/MBEC) by ≥8-fold when a PDE activator is co-administered with a standard-of-care antibiotic, relative to antibiotic alone against the same biofilm, across at least 4 of 6 ESKAPE species tested. The hypothesis is falsified if the fold-reduction in effective MIC is <8-fold in ≥3 of 6 species tested under matched conditions, or if c-di-GMP reduction/dispersal is not causally linked to MIC shift (e.g., via genetic PDE overexpression controls).

Disproof criteria:
  1. Fold-change in effective MIC/MBEC (PDE activator + antibiotic vs antibiotic alone) is <8-fold in ≥50% of species/strain combinations tested (n≥3 biological replicates each).
  2. No statistically significant reduction (p>0.05, ANOVA with correction) in intracellular c-di-GMP measured by LC-MS/MS or riboswitch-reporter fluorescence at pharmacologically relevant PDE activator concentrations.
  3. Dispersal (biofilm biomass loss) occurs but MIC shift does not follow — indicating dispersal and killing are decoupled (would falsify the causal chain, not just the magnitude).
  4. Genetic PDE-overexpression control strains (constitutive c-di-GMP depletion) fail to reproduce the ≥8-fold MIC shift seen with pharmacological activation — indicating off-target drug effects rather than the proposed mechanism.
  5. Effect is fully explained by direct antibiofilm/antibacterial activity of the "PDE activator" compound itself (i.e., activity persists in PDE-knockout strains) rather than by c-di-GMP-mediated dispersal.

Spine & Adversarial Read

  • highThe 8-fold MIC threshold is an arbitrary round number with no cited pharmacodynamic or clinical justification tying it to a therapeutically meaningful outcome — why 8-fold and not 4-fold or 16-fold?
    8-fold aligns with typical CLSI breakpoint doubling-dilution steps (3 twofold dilutions) representing the difference between 'resistant' and 'susceptible' categorical calls in many antibiotics, giving it clinical interpretability; however, the EVP does not empirically justify why this specific magnitude was chosen over pre-registering an effect-size-agnostic dose-response characterization. This is a genuine unresolved gap — the threshold should be treated as a pre-specified但 somewhat arbitrary pharmacodynamic convenience rather than a mechanistically derived number.
  • highNo live literature search was available, so the claim that this is novel relative to existing dispersal-agent + antibiotic combination studies (e.g., nitric oxide donors, D-amino acids, cis-2-decenoic acid, or known PDE-activating small molecules already published in Pseudomonas biofilm literature) cannot be verified — this may substantially overlap with existing published work.
    CLOSEST_EXISTING_WORK is empty due to unavailable search infrastructure, not because prior art doesn't exist. Before committing the full $640K budget, a mandatory literature review (2-3 weeks, <$10K) must be completed to confirm whether ≥8-fold MIC restoration via chemical dispersal has already been demonstrated in at least a subset of these pathogens, which would narrow this EVP's novel contribution to the pan-ESKAPE generalization and genetic-mechanism-confirmation components only, not the core dispersal-restores-susceptibility concept.
  • mediumWhy was MBEC/CFU-based CLSI-adapted assay chosen as the primary methodology rather than time-kill kinetics, in vivo biofilm models, or single-cell reporter-based persistence assays, which might better capture the sessile-to-planktonic phenotypic conversion this hypothesis actually claims?
    MBEC/CFU endpoints were chosen for standardization, reproducibility, and cross-lab comparability (CLSI-adapted protocols are widely validated and lower-cost than in vivo models), and the protocol adds RT-qPCR motility-gene and CLSM architecture readouts specifically to address the phenotypic-conversion claim beyond simple killing. However, the EVP does not include single-cell-resolution persister/dormancy assays (e.g., flow cytometry with metabolic dyes), which would more directly test the 'sessile-to-planktonic mode conversion' mechanism rather than inferring it indirectly from population-level MIC shift — this is an acknowledged methodological gap that could be addressed in a follow-up single-cell validation phase if population-level results are positive.

Experimental Protocol

Design: 3-arm comparative, dose-response, in vitro biofilm-MBEC assay with genetic and pharmacological controls, across 6 ESKAPE species (2 clinical + 2 reference strains each = minimum 24 strains).

Arms: (1) antibiotic alone (dose range 0.03–128× CLSI MIC), (2) antibiotic + PDE activator (fixed sub-toxic activator dose, established in Phase 0 dose-ranging), (3) antibiotic + vehicle control. Parallel genetic arm: isogenic PDE-overexpression (inducible) vs PDE-catalytically-dead mutant, same antibiotic dose range.

Primary readout: MBEC50/MBEC90 (minimum biofilm eradication concentration, CLSI M07/M100-adapted biofilm protocol) via CFU enumeration after biofilm disruption/sonication and plating.

Secondary readouts: intracellular c-di-GMP (LC-MS/MS, normalized to protein), biofilm biomass (CV assay, OD590), biofilm architecture (CLSM with LIVE/DEAD + biovolume via COMSTAT2), planktonic conversion marker (motility gene expression, RT-qPCR of flagellar/pili regulon).

Required datasets:
  • CLSI/EUCAST reference MIC panels for all 24 strains (existing public databases + in-house baseline determination).
  • ATCC/BEI Resources reference ESKAPE strains + ≥2 clinical isolates per species (biobank or hospital microbiology partnership required).
  • Validated c-di-GMP LC-MS/MS standard curves (synthetic c-di-GMP standard, commercially available, Biolog/Sigma).
  • c-di-GMP riboswitch fluorescent reporter plasmids (e.g., Cdrap/Riboswitch-GFP constructs; available from published academic sources, e.g., Waters lab / Sondermann lab plasmid repositories via Addgene — to be sourced under MTA).
  • Isogenic PDE-overexpression and catalytically-dead mutant strain sets (constructed in-house via allelic exchange, 8–12 weeks lead time).
  • CDC biofilm reactor or Calgary Biofilm Device (MBEC assay plates, Innovotech) for standardized mature biofilm generation.
  • Panel of ≥3 candidate small-molecule PDE activators (literature-sourced or commercial screening hits; if none exist as validated tool compounds, this becomes a rate-limiting dependency — flagged below).
Success:
  • Primary: ≥8-fold median reduction in MBEC90 (Arm B vs Arm A) in ≥4/6 species, statistically significant (p<0.01, corrected).
  • c-di-GMP reduction ≥70% within 2h in same strains showing MBEC shift.
  • Genetic PDE-overexpression control reproduces ≥6-fold MBEC shift (concordance with pharmacological arm, confirming mechanism, not off-target effect).
  • Spearman r>0.6 between per-strain c-di-GMP depletion and MBEC fold-shift.
  • PDE activator alone shows <10% direct bactericidal activity (rules out confound).
Failure:
  • <8-fold MBEC shift in ≥3/6 species.
  • No dose-response relationship between activator concentration and c-di-GMP depletion.
  • Genetic control fails to replicate pharmacological effect (mechanism not confirmed — likely off-target drug activity).
  • PDE activator shows direct antibacterial activity >20% at working concentration (confound invalidates attribution).
  • High strain-to-strain variance (CV>100%) precluding reproducible effect size estimation.

ROI Projection

Implementation Sketch

PHASE0_compound_screen(if no validated PDE activator exists):
    for compound in library[2000-5000]:
        activity = purified_PDE_enzyme_assay(compound)  # fluorescence/HPLC c-di-GMP hydrolysis
        if activity > threshold: candidates.append(compound)
    top_hits = rank(candidates, top_n=5)

for species in ESKAPE_panel[6]:
  for strain in [reference, clinical_isolate_1, clinical_isolate_2]:
    biofilm = grow_CDC_biofilm(strain, hours=24-72)
    baseline_cdiGMP = LC_MS(biofilm, t=0)
    for activator_dose in dose_range:
        treated = expose(biofilm, activator_dose)
        cdiGMP_t = LC_MS(treated, timepoints=[0,0.5,1,2,4])
        dispersal = CV_assay(treated) + CLSM_COMSTAT2(treated)
        for antibiotic in [aminoglycoside, fluoroquinolone, beta_lactam]:
            for ab_dose in log2_dilution_series:
                MBEC = CFU_enumeration(treated, antibiotic, ab_dose)
        record(strain, activator_dose, cdiGMP_t, dispersal, MBEC_curve)
  genetic_control = repeat_above(strain=isogenic_PDE_overexpression_and_dead_mutant)

analysis:
    fold_MBEC_shift = MBEC90[armA] / MBEC90[armB]
    mixed_effects_model(fold_MBEC_shift ~ treatment + (1|strain))
    correlate(cdiGMP_depletion, fold_MBEC_shift)  # causality check
    compare(pharmacological_arm, genetic_control_arm)  # mechanism specificity check
Abort checkpoints:
  • Day 30 (Phase 0 gate): if no compound achieves ≥50% PDE activation in enzymatic assay, abort/re-scope before biological testing (saves ~70% of total budget).
  • Day 90: if c-di-GMP depletion <30% in first 2 species tested at maximum tolerated dose, abort remaining species and re-evaluate compound choice.
  • Day 150: if genetic PDE-overexpression control fails to show ≥4-fold MBEC shift (mechanism not confirmed even in idealized genetic system), abort pharmacological arm entirely — indicates hypothesis itself may be wrong, not just compound potency.
  • Day 210: interim analysis on first 3 species; if median fold-shift <4-fold, downgrade remaining scope to mechanistic characterization only (do not proceed to full 6-species/24-strain panel).

Source

AegisMind Research
Need AI to work rigorously on your problems? AegisMind uses the same multi-model engine for personal and professional use. Get started